Combination Sitagliptin, Tacrolimus, Sirolimus for Prophylaxis of Acute Graft-vs-Host-Disease
Investigators aimed to determine whether DPP-4 inhibition reduces the incidence of acute graft-vs-host disease among patients receiving allogeneic HSCT.
Home
Reduced-Intensity Conditioning May Not Improve Post Allogeneic HSCT Outcomes in AML
A sequenced reduced-intensity conditioning regimen may not improve outcomes for patients with acute myeloblastic leukemia and myelodysplasia after allogeneic stem cell transplantation.
Uncertainties Surround Optimal Dosing of Cytarabine in AML
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
Dexamethasone May Not Improve Outcomes in Chronic Subdural Hematoma
Treatment of symptomatic chronic subdural hematoma with dexamethasone may worsen outcomes compared with placebo.
Outcomes of Adding a Fourth Chemotherapy Course in AML
For patients with acute myeloid leukemia, a total of 4 courses of chemotherapy may improve relapse rates but not overall survival, compared with 3 total courses of treatment.
PARP Inhibition Associated With Increased Risk for Secondary MDS, AML
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Two Billion COVID-19 Vaccine Doses From BioNTech Expected This Year
Company also looking to widen eligibility for the vaccine to include pregnant women, children, and others.
Current Treatment Options for Pregnancy-Related Venous Thromboembolism
A recently published review outlines the approach to the treatment of venous thromboembolism in pregnancy using patient case studies from their clinical practice in a Netherlands-based academic hospital.
Idelalisib Does Not Increase Risk for Bleeding in Patients With CLL, Indolent NHL Receiving Anticoagulation/Antiplatelet Therapy
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Study Finds Low Adherence to Lenalidomide Therapy in Multiple Myeloma
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
